KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of SDT-001, a dual-task digital device, in managing attention-deficit/hyperactivity disorder symptoms in children and adolescents: a phase 3, randomized, standard treatment-controlled study.

Katsunaka Mikami, Tasuku Miyajima, Ryo Nishino, Naohiro Kawazoe, Yousuke Kinoshita, Takashi Okada, Hiroki Fukuju

Psychiatry Clin Neurosci 79(8) 447-457

PMID40317565
PMCIDPMC12319664
DOI10.1111/pcn.13833
发表日期2025-05-03
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 multi panel km;Fig. 3:AI 判定为 other。
摘要

摘要

AIM: This phase 3, multicenter, open-label study aimed to evaluate the efficacy and safety of SDT-001, a dual-task digital device, compared to standard treatment (environmental and/or psychosocial treatment: treatment as usual; TAU) in the comparison part and to evaluate the safety, tolerability, and long-term efficacy of SDT-001 in the repetition part in Japanese children and adolescents with attention-deficit/hyperactivity disorder (ADHD). METHODS: In the comparison part, participants on standard treatment were randomized (2:1) to SDT-001 (n = 109; 25 min/day for 6 weeks, with a 4-week follow-up) or TAU (n = 55) groups. Participants (n = 126) from the comparison part transitioned to a single-arm repetition part with SDT-001 (6 weeks and followed for 12 weeks). Primary endpoint in the comparison part was changed from baseline to 6 weeks in ADHD rating scale IV (ADHD-RS-IV) inattention scores. RESULTS: In the comparison part, SDT-001 demonstrated superiority to TAU, with significantly greater improvements from baseline to week 6 in ADHD-RS-IV inattention (adjusted mean difference [95% confidence interval], -2.97 [-4.38, -1.56]; P < 0.0001), total (-4.56 [-6.75, -2.38]; P < 0.0001), and hyperactivity-impulsivity (-1.55 [-2.64, -0.46]; P = 0.0056) scores. Additionally, other secondary endpoints showed improvements in symptoms in the SDT-001 group. In the repetition part, SDT-001 showed sustained reductions in ADHD-RS-IV scores till 12 weeks after completion of the 6-week treatment. No new severe adverse events or safety concerns were reported. CONCLUSION: SDT-001 demonstrated superior efficacy at week 6 in ADHD-RS-IV compared to TAU, and reductions in scores were maintained up to the following 12 weeks, indicating its potential as a novel digital therapeutic option for ADHD management.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Participant disposition (CONSORT flowchart). ADHD‐RS‐IV, attention‐deficit/hyperactivity disorder rating scale IV; FAS, full analysis set; SDT‐001, investigational digital therapeutic; TAU, treatment as usual.
非 KM Figure
Fig. 2Fig. 2 Change from baseline in ADHD‐RS‐IV (physicians' assessment) (a) inattention subscale score, (b) total score, and (c) hyperactive–impulsive subscale score during the treatment period and subsequent follow‐up period in the comparison part (FAS). *Statistical significance was determined with P < 0.05. A mixed‐effect model for repeated measures with unstructured covariance was applied to the change from baseline in score from week 2 to week 6 as response. This model was based on group, timepoint (week 2 to week 6) and interaction between group and timepoint as fixed effects, value at the baseline, binarized age group (≤12 years, ≥13 years), prior ADHD medication (yes/no), and ADHD type (combined, predominantly inattentive, predominantly hyperactive–impulsive) as covariates. ADHD‐RS‐IV, attention‐deficit/hyperactivity disorder rating scale IV; FAS, full analysis set; SD, standard deviation; SDT‐001, investigational digital therapeutic; TAU, treatment as usual.
非 KM Figure
Fig. 3Fig. 3 Change from baseline in ADHD‐RS‐IV (physician's assessment) (a) total score, (b) inattention subscale score, and (c) hyperactive–impulsive subscale score in the repetition part. ADHD‐RS‐IV, attention‐deficit/hyperactivity disorder rating scale IV; SD, standard deviation; SDT‐001, investigational digital therapeutic; TAU, treatment as usual.
非 KM Figure